CD7-targeted CAR-T therapy for relapsed blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a specific marker called CD7 on blood cancer cells. It is for people whose blood cancer has not responded to other treatments or has come back after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is a blood cancer (like leukemia or lymphoma) that has come back or not responded to standard treatments.
- Your cancer cells have a marker called CD7 (your doctor can test for this).
- You are generally active and able to care for yourself (ECOG score 0-2).
- Your heart, liver, and kidneys are working well enough (tests will check this).
- No active infections, other cancers, or serious medical conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (T cells) that are modified to target a protein called CD7 found on certain blood cancer cells. It is designed for people whose T-cell or myeloid leukemia has come back or hasn't responded to other treatments.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a new treatment made from your own immune cells (NK cells) that are modified to recognize and attack cancer cells with a marker called CD7. It is for people whose blood cancer has returned or not improved with other treatments.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.